Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

1.58USD
23 Aug 2019
Change (% chg)

$-0.18 (-10.23%)
Prev Close
$1.76
Open
$1.76
Day's High
$1.76
Day's Low
$1.58
Volume
51,715
Avg. Vol
155,626
52-wk High
$2.57
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Fortress Biotech Reports Q1 Earnings Per Share $0.03
Friday, 10 May 2019 

May 10 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q1 EARNINGS PER SHARE $0.03.Q1 REVENUE $6.5 MILLION VERSUS $5.9 MILLION.  Full Article

Fortress Biotech Reports Fourth Results
Monday, 18 Mar 2019 

March 18 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.FORTRESS BIOTECH - AS OF DEC 31, 2018, CO'S CONSOLIDATED CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH TOTALED $99.2 MILLION.  Full Article

Fortress Anticipates Launching At Least 1 Or 2 New Prescription Drugs In 2019
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH INC - ANTICIPATE JOURNEY MEDICAL CORPORATION WILL GENERATE NET SALES EXCEEDING $20 MILLION IN 2018.FORTRESS BIOTECH INC - ANTICIPATE LAUNCHING AT LEAST ONE OR TWO NEW PRESCRIPTION DRUGS IN 2019..  Full Article

Fortress Biotech Q3 Loss Per Share $0.37
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.37.Q3 REVENUE $63.7 MILLION VERSUS $46.9 MILLION.  Full Article

Fortress Biotech Q2 Loss Per Share $0.50
Friday, 10 Aug 2018 

Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $63.8 MILLION VERSUS $50.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.  Full Article

Mustang Bio Q1 Loss Per Share $0.24
Tuesday, 15 May 2018 

May 14 (Reuters) - Mustang Bio ::MUSTANG BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.MUSTANG BIO - Q1 LOSS PER SHARE $0.24.  Full Article

Fortress Biotech Reports FY Revenue Of $187.6 Mln
Friday, 16 Mar 2018 

March 16 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.SAYS FY REVENUE $187.6 MILLION.‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, CASH DEPOSITS, RESTRICTED CASH TOTALED $168.3 MILLION​.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article